Anti-tumor activity of erlotinib in the BxPC-3 pancreatic cancer cell line

Table 1 PCR primers

Target genes		Primer sequence	Size (bp)	Annealing temperature (°C)	Cycles
Bcl-2	Sense	5'-GGTGCCACCTGTGGTCCACCT-3'	458	54	35
	Antisense	5'-CCTCACTTGTGGCCCAGATAGG-3'
Bax	Sense	5'-CTGACATGTTTTCTGACGGC-3'	289	54	35
	Antisense	5'-TCAGCCCATCTTCTTCCAGA-3'
Bcl-xl	Sense	5'-TTGGACAATGGACTGGTTG-3'	765	54	35
	Antisense	5'-GTAGAGTGGATGGTCAGTG-3'
Bak	Sense	5'-TGAAAAATGGCTTCGGGGCAAGGC-3'	642	54	35
	Antisense	5'-TCATGATTTGAAGAATCTTCGTACC-3'
GAPDH	Sense	5'-CATGCCAGTGAGCTTCCCGTT-3'	408	56	35
	Antisense	5'-GTGGAGTCTACTGGCGTCTTC-3'
VEGF	Sense	5'-ATGAACTTTCTGCTGTCTTG-3'	382	54	35
	Antisense	5'-TGCATGGTGATGTTGGAC-3'

Table 2 Cell cycle analysis (%, mean ± SD)

Group	G0/G1	S	G2/M
Control	63.31 ± 0.99	25.28 ± 0.88	11.40 ± 1.68
Erlotinib	73.40 ± 1.34b	14.15 ± 0.99b	12.44 ± 1.95

^bP < 0.01 vs control group.